ADHD Spokesperson, Celebrity Team Up Announcing VYVANSE For Adult ADHD Treatment
Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has launched VYVANSE (lisdexamfetamine dimesylate) for the treatment of adults with Attention Deficit Hyperactivity Disorder (ADHD). This launch of adult ADHD treatment follows the recent FDA approval of VYVANSE to treat ADHD in the adult population. VYVANSE is now available in U.S. pharmacies nationwide in six once-daily dosage strengths. To raise awareness of ADHD in adults and recognize the launch of VYVANSE for adults, Shire has partnered with celebrity designer Ty Pennington to shine the spotlight on living as an adult with ADHD. Pennington takes VYVANSE as part of his treatment plan to manage his ADHD symptoms so he can focus and get work done.
Pennington returns today to his hometown of Atlanta, where he will visit the Savannah College of Art and Design-Atlanta (SCAD-Atlanta) and announce the Daily Successes with ADHD Scholarship for an adult with ADHD who is pursuing an education or career in a creative field at SCAD-Atlanta. The $10,000 scholarship, sponsored by Shire, the maker of VYVANSE, will benefit an adult with ADHD who is enrolled in, or applying to, a graduate program at the art institution. The objective of the scholarship is to recognize achievements, and to motivate a student to continue to focus and achieve daily successes.
"As an adult with ADHD, I know, firsthand, the importance of understanding and treating ADHD. I believe if I'd been diagnosed and treated earlier, I would have struggled less as a child," said Ty Pennington, host of ABC's Extreme Makeover: Home Edition™. "Today, I have a very demanding schedule with long production days and constant travel, and I take VYVANSE to help control my ADHD symptoms so that I can focus and organize."
ADHD Can Affect Adults' Daily Lives In adults with ADHD, symptoms can impact their professional life, social life, relationships and personal finances. In a new survey conducted by Shire of adults who experienced ADHD symptoms in a typical week, 88 percent of 328 adults surveyed reported that they have difficulty organizing tasks and activities, while 89 percent of 381 of these adults had difficulty finishing things, such as projects or work at home. These adults reported that this has had a negative impact on their daily life and activities. Additionally, among the 347 adults surveyed who are currently employed, 66 percent felt that they would do a better job at work if they were more focused and organized.
"Although ADHD can affect children and adults, the core symptoms of the disorder, inattention, hyperactivity, and impulsivity, may present differently in these two patient groups. For example, hyperactivity may present in adults as inner restlessness and inattention may present as a lack of focus and organization, poor time management, and an inability to finish tasks," said David W. Goodman, M.D., director of the Adult Attention Deficit Disorder Center of Maryland and assistant professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine. VYVANSE is one of several treatment options that may provide effective treatment control for adults with ADHD. In a clinical study, VYVANSE was shown to significantly improve ADHD symptoms within the first week: inattention - such as the ability to focus and organize - and hyperactivity and impulsivity - such as restlessness, and interrupting."
Shire received approval in April 2008 from the FDA for VYVANSE for the treatment of ADHD in adults aged 18 to 55 years. VYVANSE was introduced in July 2007 for the treatment of ADHD in children aged 6 to 12 years. VYVANSE is available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. In its first year of availability, more than 2 million VYVANSE prescriptions have been filled.
VYVANSE works with the body's natural metabolism to deliver active medication. VYVANSE is a once-a-day capsule that should be taken in the morning with or without food as prescribed by your doctor.
Additional information about VYVANSE and Full Prescribing Information are available at http://www.vyvanse.com.
Vyvanse is indicated for the treatment of ADHD. Efficacy based on two controlled trials in children aged 6 to 12 and one controlled trial in adults.
Tell the doctor about any heart conditions, including structural abnormalities, that you, your child, or a family member, may have. Inform the doctor immediately if you or your child develops symptoms that suggest heart problems, such as chest pain or fainting.
Vyvanse should not be taken if you or your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.